InVivium Capital, a venture capital firm based in Chicago, led a $45m Series C funding round in Alto Neuroscience, a precision psychiatry developing targeted medicines designed to help patients get better faster, with participation from Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, and Windham Venture Partners. “We deeply appreciate the support from investors who fully understand the potential of our precision psychiatry approach, which we believe can help alleviate the significant burden of disease that remains in the treatment of mental health conditions. This financing allows us to bring our clinical programs through key value-generating milestones and significantly extends our operational runway,” Amit Etkin, Alto Neuroscience Founder and CEO.